Stevens Capital Management LP Buys New Position in Gilead Sciences, Inc. $GILD

Stevens Capital Management LP acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 46,038 shares of the biopharmaceutical company’s stock, valued at approximately $5,110,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC raised its holdings in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 84 shares during the period. Hemington Wealth Management boosted its holdings in shares of Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 85 shares during the period. Ignite Planners LLC increased its position in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 86 shares during the last quarter. Archer Investment Corp grew its holdings in Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 87 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Gilead Sciences by 0.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after buying an additional 87 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 earnings beat and firm guidance: Gilead reported $1.86 EPS vs. $1.83 est. and $7.93B revenue (above estimates) and set FY‑2026 EPS guidance of $8.45–$8.85 — a catalyst for re-rating. Analyst Reactions Post‑Earnings
• Positive Sentiment: Argus raised its price target to $165 and kept a Buy rating, adding analyst-driven upside (~mid-single digits vs. current levels). Argus PT Raise
• Positive Sentiment: Mizuho lifted its target to $170 and kept an Outperform rating, supporting a higher consensus valuation and momentum for buy‑side flows. Mizuho PT Raise
• Neutral Sentiment: Barclays initiated coverage with an Equal‑Weight rating and $155 target — neither a strong buy nor a sell signal, but it provides fresh institutional coverage. Barclays Coverage
• Neutral Sentiment: Broader analyst and media coverage (Zacks, Yahoo, Benzinga retrospectives) is keeping GILD in focus for retail/institutional investors; these pieces inform positioning but are mixed in directional impact. Zacks Coverage
• Neutral Sentiment: Short‑interest data in the feed looks anomalous/zeroed out and provides no clear sell pressure signal at present (data likely noisy).
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares (~$154.43 avg price) — a small amount but negative for sentiment when combined with other insider moves. CFO Form 4
• Negative Sentiment: Material insider sale: Johanna Mercier sold 28,000 shares (~$154.44 avg), an ~18.9% reduction in her holding — a larger ticket that can weigh on investor confidence. Mercier Form 4
• Negative Sentiment: “Time to take profits” / rating downgrade commentary is circulating, which can trigger short‑term selling from momentum traders. Seeking Alpha Take‑Profits Piece

Gilead Sciences Price Performance

Gilead Sciences stock opened at $151.40 on Friday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The firm has a market capitalization of $187.84 billion, a price-to-earnings ratio of 22.36, a PEG ratio of 2.01 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The company has a fifty day simple moving average of $133.47 and a 200-day simple moving average of $123.63.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the company posted $1.90 EPS. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 319,891 shares of company stock worth $45,091,556 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Scotiabank raised their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Citigroup increased their price objective on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, TD Cowen lifted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.